U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07213674) titled 'A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer' on Sept. 18.
Brief Summary: The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Study Start Date: Nov. 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-resistant Prostate Cancer
Intervention:
DRUG: Xaluritamig
Xaluritamig will be administered IV.
DRUG: Abiraterone acetate
Abiraterone acetate will be administere...